The deal has been announced just a few days after the FDA lifted a clinical hold on a phase 1/2 trial of VX-880 – a stem cell therapy Vertex acquired through its near $1 billion acquisition of ...
Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...
Vertex’s Alyftrek is a once-daily oral CFTR modulator that works by correcting the malfunctioning protein made by the CFTR gene. The MHRA’s approval of the therapy was based on positive results from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback